[Abstract Only] Randomized trials: Efficacy and safety of a plant-derived influenza vaccine in adults
14 Oct, 2020 | 09:23h | UTCEfficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
NEW—First large-scale studies of plant-derived, quadrivalent, virus-like particle influenza vaccine show substantial protection against respiratory illness & influenza-like illness caused by influenza viruses in adults: two randomised phase 3 trials https://t.co/oQbs2uJTXY pic.twitter.com/C6b6Qi6qZ7
— The Lancet (@TheLancet) October 13, 2020